Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18878473 | 1.00 | OPRD1 (0.64) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL12836600 | 1.00 | OPRD1 (0.64) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL21226454 | 1.00 | OPRD1 (0.64) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL684700 | 0.86 | OPRM1 (0.48) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL18994809 | 0.86 | OPRM1 (0.67) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL327364 | 0.84 | OPRM1 (0.67) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL19919122 | 0.84 | OPRM1 (0.67) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL12836597 | 0.84 | OPRM1 (0.67) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL12831723 | 0.84 | OPRM1 (0.67) | OPRD1OPRM1OPRK1LMNAPDE4D | |
| SCHEMBL18994760 | 0.84 | OPRD1 (0.46) | OPRD1OPRM1OPRK1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464291-B1 | SUPPORTED METAL CATALYST FOR THE PRODUCTION OF HYDROMORPHONE | SIEGFRIED AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-10370382-B2 | Process for preparing hydromorphone and derivatives thereof | CAMBREX CHARLES CITY, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-9981978-B2 | Preparation of saturated ketone morphinan compounds by catalytic isomerisation | CAMBREX CHARLES CITY, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981978-B2 | Preparation of saturated ketone morphinan compounds by catalytic isomerisation | CAMBREX CHARLES CITY, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2017211879-A1 | SUPPORTED METAL CATALYST FOR THE PRODUCTION OF HYDROCODONE AND HYDROMORPHONE | SIEGFRIED AG (CH) | 2017-12-14 | — | — | WO | disclosed |
| US-9775840-B2 | Peripherally acting opioid compounds | ALKERMES, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2017017436-A1 | NEW PROCESS FOR PREPARING HYDROMORPHONE AND DERIVATIVES THEREOF | CAMBREX CHARLES CITY, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| US-20160168159-A1 | PREPARATION OF SATURATED KETONE MORPHINAN COMPOUNDS BY CATALYTIC ISOMERISATION | CAMBREX CHARLES CITY, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160168159-A1 | PREPARATION OF SATURATED KETONE MORPHINAN COMPOUNDS BY CATALYTIC ISOMERISATION | CAMBREX CHARLES CITY, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | SHIRE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC | 2011-01-20 | — | — | US | disclosed |
| US-20090192095-A1 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | SHIRE LLC (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168159-A1 | PREPARATION OF SATURATED KETONE MORPHINAN COMPOUNDS BY CATALYTIC ISOMERISATION | ADH1C, ADH1A, ADH5 | OPRD1 170/4885OPRM1 114/4885OPRK1 104/4885 |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | OPRL1, OPRM1, DNPEP | OPRD1 6/4885OPRM1 2/4885OPRK1 4/4885 |
| US-10370382-B2 | Process for preparing hydromorphone and derivatives thereof | CYP1A1, DHPS, CYP11B1 | OPRD1 9/4885OPRM1 5/4885OPRK1 11/4885 |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | OPRL1, OPRM1, DNPEP | OPRD1 7/4885OPRM1 2/4885OPRK1 4/4885 |
| US-20090192095-A1 | AMINO ACID AND PEPTIDE PRODRUGS OF OPIOID ANALGESICS WITH REDUCED GI SIDE-EFFECTS | OPRL1, OGFR, OPRK1 | OPRD1 8/4885OPRM1 5/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.